EMA Authorised: Vumerity (Diroximel fumarate (BIIB098)) — Biogen Netherlands B.V.

View source ↗

Summary

EMA authorised Vumerity (diroximel fumarate) for relapsing-remitting multiple sclerosis, adding a new disease-modifying therapy to Biogen's EU portfolio. Biogen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• VUMERITY (diroximel fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Biogen Netherlands B.V.. Decision date: 04/02/2025